ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products is medical classification list by Centers for Medicare and Medicaid Services (CMS).
ICD-10-PCS code range (XW0), contains ICD-10-PCS codes for Nervous System, New Technology, Anatomical Regions, Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
PCS Tables
| X New Technology |
| W Anatomical Regions |
| 0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
|---|---|---|---|
| Character 4 | Character 5 | Character 6 | Character 7 |
Body System (Character 4)
0 Skin | Approach (Character 5) X External | Substance (Character 6) 2 Anacaulase-bcdb | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 1 Daratumumab and Hyaluronidase-fihj | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Talquetamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 4 Teclistamab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Satralizumab-mwge | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal AntibodyH Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Elranatamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S COVID-19 Vaccine Dose 1 | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Epcoritamab Monoclonal Antibody | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) T COVID-19 Vaccine Dose 2U COVID-19 Vaccine | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) V COVID-19 Vaccine Dose 3 | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) W COVID-19 Vaccine Booster | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) X External | Substance (Character 6) 2 Anacaulase-bcdb | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
2 Muscle | Approach (Character 5) 0 Open | Substance (Character 6) D Engineered Allogeneic Thymus Tissue | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
2 Muscle | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S COVID-19 Vaccine Dose 1T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
2 Muscle | Approach (Character 5) 3 Percutaneous | Substance (Character 6) V COVID-19 Vaccine Dose 3W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Brexanolone | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Spesolimab Monoclonal Antibody | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Nerinitide3 Durvalumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Narsoplimab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Mosunetuzumab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Terlipressin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Afamitresgene Autoleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Coagulation Factor Xa, Inactivated | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Trilaciclib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Tabelecleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Lurbinectedin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Treosulfan | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Ceftolozane/Tazobactam Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Inebilizumab-cdon | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Cefiderocol Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Ciltacabtagene Autoleucel | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Cytarabine and Daunorubicin Liposome Antineoplastic | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Omadacycline Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Amivantamab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Eculizumab | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) D Atezolizumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Remdesivir Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Etesevimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Bamlanivimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Sarilumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Tocilizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Other New Technology Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Axicabtagene Ciloleucel ImmunotherapyJ Tisagenlecleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Fosfomycin Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Idecabtagene Vicleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Sulbactam-Durlobactam | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L CD24Fc Immunomodulator | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Lifileucel ImmunotherapyM Brexucabtagene Autoleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Meropenem-vaborbactam Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Lisocabtagene Maraleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) P Glofitamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q Tagraxofusp-erzs Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q PosoleucelR Rezafungin | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Iobenguane I-131 AntineoplasticU Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Brexanolone | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Spesolimab Monoclonal Antibody | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Nerinitide3 Durvalumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Narsoplimab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Mosunetuzumab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Terlipressin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Afamitresgene Autoleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Coagulation Factor Xa, Inactivated | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Trilaciclib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Tabelecleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Lurbinectedin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Treosulfan | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Ceftolozane/Tazobactam Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Inebilizumab-cdon | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Cefiderocol Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Ciltacabtagene Autoleucel | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Cytarabine and Daunorubicin Liposome Antineoplastic | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Omadacycline Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Amivantamab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Eculizumab | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) D Atezolizumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Remdesivir Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Etesevimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Bamlanivimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Sarilumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Tocilizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Other New Technology Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Axicabtagene Ciloleucel ImmunotherapyJ Tisagenlecleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Fosfomycin Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Idecabtagene Vicleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Sulbactam-Durlobactam | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L CD24Fc Immunomodulator | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Lifileucel ImmunotherapyM Brexucabtagene Autoleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Meropenem-vaborbactam Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Lisocabtagene Maraleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) P Glofitamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q Tagraxofusp-erzs Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q PosoleucelR Rezafungin | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Iobenguane I-131 AntineoplasticU Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
5 Peripheral Artery | Approach (Character 5) 3 Percutaneous | Substance (Character 6) T Melphalan Hydrochloride Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
9 Nose | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Esketamine Hydrochloride | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 3 Maribavir Anti-infective | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 8 Uridine Triacetate | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) F Other New Technology Therapeutic SubstanceJ Apalutamide Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) J Quizartinib Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) K Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) L Erdafitinib Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) N SER-109 | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) R Venetoclax Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) T RuxolitinibV Gilteritinib Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) 3 Maribavir Anti-infectiveK Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
G Upper GI | Approach (Character 5) 8 Via Natural or Artificial Opening Endoscopic | Substance (Character 6) 8 Mineral-based Topical Hemostatic Agent | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) 3 Maribavir Anti-infectiveK Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) X Broad Consortium Microbiota-based Live Biotherapeutic Suspension | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
H Lower GI | Approach (Character 5) 8 Via Natural or Artificial Opening Endoscopic | Substance (Character 6) 8 Mineral-based Topical Hemostatic Agent | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
Q Cranial Cavity and Brain | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 1 Eladocagene exuparvovec | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
V Bones | Approach (Character 5) 0 Open | Substance (Character 6) P Antibiotic-eluting Bone Void Filler | Qualifier (Character 7) 7 New Technology Group 7 |
January 01, 1970
Novitas and FCSO will require documentation for certain pathology and laboratory claims. Medicare Administrative Contractors MAC Novitas Solutions and First Coast Service Options FCSO recently announc... [ Read More ]
January 01, 1970
Potential erroneous Medicare payments million to treat patients with opioid use disorder OUD are estimated at 17.8 million. The opioid crisis in the United States has led to record numbers of people d... [ Read More ]
January 01, 1970
Get an overview of key updates to the postacute care quality reporting programs for 2025. The Centers for Medicare 38 Medicaid Services is offering a crosssetting webbased training course that provide... [ Read More ]
January 01, 1970
Hospitals should use this tool to protect their profit margins. Diagnosisrelated group DRG validation ensures the accuracy of DRG assignment and payment for inpatient hospital stays. Since inpatient c... [ Read More ]
January 01, 1970
Meet a member who has made an indelible impression in the healthcare industry. AAPCs Member of the Month Nancy Reading RN BS CPC CPCP CPCI is a longtime member and a pillar in the healthcare community... [ Read More ]
... [ Read More ]